Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
EPAD and AMYPAD presented at the CTAD conference
EPAD and AMYPAD presented at the CTAD conference 03 Nov 2017 AMYPAD was mentioned at the CTAD conference in Boston......
AMYPAD project holds its GA meeting in Amsterdam
AMYPAD project holds its GA meeting in Amsterdam 10 Oct 2017 The AMYPAD consortium gathered for their General Assembly meeting in Amsterdam, The Netherlands....
Interview with Isadora Lopes Alves
Interview with Isadora Lopes Alves 28 Aug 2017 As a postdoctoral researcher working at the VUmc team, I have two main roles in AMYPAD......
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.